Identifying biomarkers in Diffuse Large B-cell Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify new prognostic biomarkers for patients with Diffuse Large B-cell Lymphoma (DLBCL) by analyzing both prospective and retrospective cohorts. It focuses on assessing progression-free survival and overall survival while characterizing the immune microenvironment through advanced transcriptomics. The study will also explore the correlation between gene expression, mutational status, and clinical outcomes using tissue samples and PET imaging. By integrating these factors, the research seeks to enhance predictive capacity beyond existing clinical factors.

Why it matters

Who can join: the full rules

Inclusion Criteria for the prospective cohort:

* New diagnosis of High grade Diffuse large B cell Lymphoma undergoing first line standard treatment;
* Signed written informed consent;
* Availability of FFPE sample.

Inclusion Criteria for the retrospective cohort:

* Diagnosis of High grade Diffuse large B cell Lymphoma from 2011 to 2017;
* Availability of FFPE sample and clinical data.

Exclusion Criteria:

* Patients included in clinical trials.

Where it's running

• Irst Irccs
  Meldola, Fc, Italy Recruiting
• Ospedale S. Maria delle Croci RAVENNA
  Ravenna, Ra, Italy Recruiting
• L'Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola-Malpighi
  Bologna, Italy Recruiting
• Ospedale Infermi
  Rimini, Italy Recruiting

Study contacts

• Principal investigator: Gerardo Musuraca, MD — Irst Irccs
• Study coordinator: Oriana Nanni, Dr
• Email: oriana.nanni@irst.emr.it
• Phone: +39 0543739100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• External beam radiation followed by bispecific antibody therapy for relapsed or refractory DLBCL

  This study tests whether giving targeted radiation first, then bispecific antibodies (epcoritamab or glofitamab), is tolerable for adults with relapsed or refractory diffuse large B-cell lymphoma.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07528352

• Chidamide maintenance for MRD-positive double-expressor DLBCL in first remission

  This study tests whether giving chidamide as maintenance therapy can help people with double-expressor DLBCL who have complete remission but still have MRD detected in their blood.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07507318

• Cognitive changes in people treated for diffuse large B‑cell lymphoma

  This study tests whether adults with newly diagnosed diffuse large B‑cell lymphoma experience cognitive changes during and after standard chemotherapy.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07443514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.